Bryce Point Capital LLC Invests $469,000 in Kenvue Inc. (NYSE:KVUE)

Bryce Point Capital LLC purchased a new stake in Kenvue Inc. (NYSE:KVUE) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 21,958 shares of the company’s stock, valued at approximately $469,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Grove Bank & Trust grew its stake in shares of Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after acquiring an additional 947 shares in the last quarter. Geneos Wealth Management Inc. acquired a new position in shares of Kenvue during the 4th quarter worth approximately $29,000. SRS Capital Advisors Inc. grew its position in shares of Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock worth $30,000 after purchasing an additional 571 shares in the last quarter. Fortitude Family Office LLC raised its position in shares of Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after buying an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc raised its position in shares of Kenvue by 300.8% in the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after buying an additional 1,441 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on KVUE shares. Canaccord Genuity Group raised their price objective on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Barclays upped their price objective on shares of Kenvue from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 27th. Royal Bank of Canada reissued a “sector perform” rating and issued a $24.00 target price on shares of Kenvue in a report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and cut their price target for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. Finally, Piper Sandler lifted their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research note on Monday, February 24th. One analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the company. According to MarketBeat, Kenvue currently has a consensus rating of “Hold” and a consensus target price of $24.00.

Kenvue Price Performance

Shares of KVUE opened at $22.33 on Friday. The business has a 50-day simple moving average of $22.59 and a two-hundred day simple moving average of $22.47. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The stock has a market cap of $42.68 billion, a PE ratio of 42.14, a PEG ratio of 2.62 and a beta of 1.25. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a $0.205 dividend. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.67%. Kenvue’s dividend payout ratio is 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.